BLOG

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

Aki Ko, chief executive officer at Elixirgen Therapeutics, sat down with NeurologyLive® at the conference to discuss the promise behind the therapy and why it can be successful in treating DMD.